LRRK2 Parkinson's Disease Fingerprint
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-80
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
About this trial
The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sample collection, a brain MRI, and a high density EEG. All data will be collected using an ad hoc electronic Case Report Form (CRF) developed for the study
Eligibility criteria
Qualifiers
age 30-80 years,
clinically established diagnosis of PD according to the Movement Disorders Society (MDS) diagnostic criteria,
Hoehn & Yahr (H&Y) stage between 1 and 3,
10 patients with a LRRK2 associated parkinsonism and 10 with sporadic PD tested with a NGS panel and MLPA for PD associated genes,
Disqualifiers
Active or history of other neurological disorders,
active infectious disease or history within the previous 4 weeks,
continuative therapy (at least 1 week) with NSAIDs or steroids within the previous 12 weeks,
active malignancy, autoinflammatory or autoimmune diseases or history within the previous 3 years;
Trial design
Treatments tested in this trial
- The interventions of the study are the study of blood biomarkers and neuroimaging and neurophysiological data
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov